Solvent-free stable lipid particle solution of palmitoylethanolamide for topical use
Eyesiu Medicines BV introduces a solvent-free, stable lipid particle solution of palmitoylethanolamide (PEA) designed for topical application to reduce hair loss associated with itchy scalps. This innovative solution enhances bioavailability and offers a fast-acting, convenient alternative to traditional PEA formulations.
Overview
Eyesiu Medicines BV has developed an innovative, solvent-free, stable lipid particle solution of palmitoylethanolamide (PEA) aimed at addressing hair loss linked to itchy scalps. This novel formulation enhances the bioavailability of PEA, a lipid known for its anti-inflammatory and cell-stabilizing properties, and is designed for topical application, providing a convenient and effective alternative to traditional capsules and creams. By targeting specific receptors involved in inflammation and cell stability, this solution offers a potentially groundbreaking approach for individuals experiencing scalp discomfort and hair loss.
Technical specifications
- Solvent-free formulation: The PEA solution is free from solvents, making it safer and more comfortable for scalp application.
- Stable lipid particle technology: Ensures enhanced bioavailability and absorption of PEA into the skin, offering fast-acting relief.
- Receptor activation: PEA interacts with PPAR-alfa, GPR55, GPR119, CB1, CB2, and TRPV1 receptors to reduce inflammation and stabilize mast cells.
- Versatile application: Can be developed into a topical cosmetic product or used as a sublingual spray for rapid action.
Technology readiness level
Currently at Technology Readiness Level 2, this solution is in the early stages of development. Future validation includes planned clinical testing in collaboration with dermatologists to evaluate the efficacy and safety in subjects with conditions such as dermatomyositis. A placebo-controlled, double-blind, randomized trial is proposed to firmly establish proof of concept within 18 months.
About Eyesiu Medicines BV
Eyesiu Medicines BV, founded in 2014 and based at the Leiden Bio Science Park in the Netherlands, specializes in the development of innovative therapeutics and nutraceuticals. The company leverages advanced nanotechnology, specifically proprietary PEGylated lipid nanoparticle delivery technology, to improve the efficacy and delivery of existing therapeutics and body-own molecules. This technology allows for the creation of solvent-free, stable formulations that can be administered via various routes, including intranasal, ocular, dermal, and inhalation, targeting inflammatory processes across neurology, ophthalmology, dermatology, and pulmonology. The company differentiates its approach by using this platform to enhance the performance of established compounds for broader clinical applications.
These advancements are significant for addressing chronic inflammatory disorders and improving patient quality of life. By optimizing the delivery of molecules like cyclosporine A and palmitoylethanolamide (PEA), Eyesiu aims to provide more effective treatments for conditions affecting the brain, eyes, lungs, skin, and hair. In addition to its preclinical pharmaceutical pipeline, the company operates a consumer healthcare division, Eyesiu Care, which offers nutraceutical products like the PEArlboost+ spray. Eyesiu continues to expand its intellectual property portfolio through international patent grants for its lipid particle formulas and actively explores product partnerships to further its research and development initiatives.
Inquire about this partnering listing
Industry applications
delivered to your inbox.